Dexrabeprazole
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
- Dexrabeprazole
- Pharmacist Assessment Report
- Dexrabeprazole: Proton pump inhibitor (acid suppressant) → duodenal obstruction
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Dexrabeprazole: Proton pump inhibitor (acid suppressant) → duodenal obstruction
One-Sentence Summary
Dexrabeprazole is an acid-suppressing drug (proton pump inhibitor) that is marketed in India. The TxGNN model predicts it may be relevant to duodenal obstruction, but no clinical trials and no publications were found to support this direction, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | duodenal obstruction |
| TxGNN Prediction Score | 0.9962 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (17 of 17) – CDSCO approval status is not included in this data |
| Number of Listed Products | 17 (valid: 17) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Dexrabeprazole is the active (right-handed) form of rabeprazole, and drugs of this class reduce stomach acid.
Duodenal obstruction is a mechanical blockage, and acid suppression has no direct effect on it. A drug of this class might help only in cases where the blockage is secondary to peptic ulcer disease, with scarring or swelling of the duodenum. This indirect link is speculative and is not supported by any trial or publication in the data compiled for this report. The high model score should therefore be treated as a hypothesis-generating signal only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 192477 | Rozydex 10mg Tablet | Strip of 10 tablets | Not recorded |
| 62833 | Dexlet 10mg Tablet | Strip of 10 tablets | Not recorded |
| 61569 | Dexarab 10mg Tablet | Strip of 10 tablets | Not recorded |
| 65356 | Dirab 5mg Tablet | Strip of 10 tablets | Not recorded |
| 59822 | Dexol 10mg Tablet | Strip of 10 tablets | Not recorded |
All 17 registered licences are currently valid. Only the first five are listed here.
Safety Considerations
- Conditions flagged as possible contraindications (not taken from label text): liver failure, liver disease, gallbladder disease, congestive heart failure, osteoporosis, postmenopausal osteoporosis, bone fracture, chronic atrophic gastritis.
No drug interaction records were found. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Duodenal obstruction is a mechanical condition with no clear acid-related mechanism, and there are no trials or publications for it. Evidence is at the model-prediction level only (L5).
To proceed, the following is needed:
- Clinical or observational studies that directly address duodenal obstruction, for example in obstruction secondary to peptic ulcer
- Mechanism of action data for dexrabeprazole
- Package insert warnings and contraindications from the Indian licences
- Review of the flagged conditions (liver disease, osteoporosis and fracture risk, heart failure) in the target population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.